2012 EDUCATIONAL BOOK - American Society of Clinical Oncology

Conclusion
Costs are rising at an unsustainable rate and, if continued,
will lead to more uninsured, less access, and more
disparity. We can bend the cost curve downward by changing
our practice patterns to provide evidence-based care,
use less-expensive drugs and tests, and increase the use of
palliative care and hospice. This will maintain quality and
decrease costs to pay for new and expensive advances.
Authors’ Disclosures of Potential Conflicts of Interest
Author
Employment or
Leadership
Positions
Consultant or
Advisory Role
ACKNOWLEDGMENT
The authors gratefully acknowledge the National Cancer
Institute, who supported this research through ACS Grant
#PEP-10-174-01 (T.S.), R01CA116227-01 (T.J.S.), 2R01CA106370-
05A1 (T.J.S.), and RC2CA148259 (B.E.H.).
Stock
Ownership Honoraria
Research
Funding
Thomas J. Smith American
Cancer Society
Bruce E. Hillner*
Ronan J. Kelly*
*No relevant relationships to disclose.
1. Organization for Economic Co-Operation and Development. OECD
Health at a Glance 2011: Health expenditure and financing. http://stats.oecd.
org/Index.aspx?DataSetCode�SHA. Acessed February 24, 2012.
2. Himmelstein DU, Thorne D, Warren E, et al. Medical bankruptcy in the
United States, 2007: results of a national study. Am J Med. 2009;122:741-746.
3. Hillner BE, Smith TJ. Efficacy does not necessarily translate to cost
effectiveness: a case study in the challenges associated with 21st-century
cancer drug pricing. J Clin Oncol. 2009;27:2111-2113.
4. Smith TJ, Hillner BE. Bending the cost curve in cancer care. N Engl
J Med. 2011;364:2060-2065.
5. Gatesman ML, Smith TJ. The shortage of essential chemotherapy drugs
in the United States. N Engl J Med. 2011;365:1653-1655.
6. Riley GF, Lubitz JD. Long-term trends in Medicare payments in the last
year of life. Health Serv Res. 2010;45:565-576.
7. Braga S. Why do our patients get chemotherapy until the end of life? Ann
Oncol. 2011;22:2345-2348.
8. Brody H. Medicine’s ethical responsibility for health care reform: the top
five list. N Engl J Med. 2010;362:283-285.
9. Emanuel EJ, Pearson SD. Physician autonomy and health care reform.
JAMA. 2012;307:367-368.
10. Snyder L. American College of Physicians Ethics Manual. Ann Intern
Med. 2012;156:73-104.
11. Merimsky O, Kovner F, Inbar M, et al. Tamoxifen for disease-negative
but MCA-positive breast cancer patients. Oncol Rep. 1997;4:843-847.
12. Rustin GJ, van der Burg ME, Griffin CL, et al. Early versus delayed
treatment of relapsed ovarian cancer (MRC OV05/EORTC 55955): a randomised
trial. Lancet. 2010;376:1155-1163.
13. Desch CE, Benson AB, Somerfield MR, et al. Colorectal cancer surveillance:
2005 update of an American Society of Clinical Oncology practice
guideline. J Clin Oncol. 2005;23:8512-8519.
14. Himmelstein DU, Thorne D, Warren E, et al. Medical bankruptcy in the
United States, 2007: results of a national study. Am J Med. 2009;122:741-746.
15. Ramsey SD, McCune JS, Blough DK, et al. Colony-stimulating factor
prescribing patterns in patients receiving chemotherapy for cancer. Am J
Manag Care. 2010;16:678-686.
16. Claxton G, DiJulio B, Whitmore H, et al. Health benefits in 2010:
premiums rise modestly, workers pay more toward coverage. Health Aff
(Millwood). 2010; Epub 2010 Sept. 2.
17. Smith TJ. The American Society of Clinical Oncology recommended
breast cancer surveillance guidelines can be done in a routine office visit.
J Clin Oncol. 2005;23:6807.
18. Loprinzi CL, Hayes D, Smith T. Doc, shouldn’t we be getting some
tests? J Clin Oncol. 2003;21:108-111.
19. Meropol NJ, Schulman KA. Cost of cancer care: issues and implications.
J Clin Oncol. 2007;25:180-186.
20. Smith TJ, Hillner BE. A way forward on the medically appropriate use
of white cell growth factors (CSFs). J Clin Oncol. In press.
21. Chan KKW, Siu E, Krahn MD, et al. A cost-utility analysis of primary
prophylaxis versus secondary prophylaxis with granulocute colony-
e50
REFERENCES
SMITH, HILLNER, AND KELLY
Expert
Testimony
Other
Remuneration
stimulating factor in elderly patients wiht diffuse aggressive lymphoma
receiving curative-intent chemotherapy. J Clin Oncol. Epub 2012 Mar 5.
22. Keating NL, Beth Landrum M, Arora NK, et al. Cancer patients’ roles
in treatment decisions: do characteristics of the decision influence roles?
J Clin Oncol. 2010;28:4364-4370.
23. Wright AA, Zhang B, Ray A, et al. Associations between end-of-life
discussions, patient mental health, medical care near death, and caregiver
bereavement adjustment. JAMA. 2008;300:1665-1673.
24. Zhang B, Wright AA, Huskamp HA, et al. Health care costs in the last
week of life: associations with end-of-life conversations. Arch Intern Med.
2009;169:480-488.
25. Freund K, Weckmann MT, Casarett DJ, et al. Hospice eligibility in
patients who died in a tertiary care center. J Hosp Med. Epub 2011 Nov 15.
26. Huskamp HA, Keating NL, Malin JL, et al. Discussions with physicians
about hospice among patients with metastatic lung cancer. Arch Intern Med.
2009;169:954-962.
27. NHPCO Facts and Figures: Hospice Care in America. Alexandria, VA:
National Hospice and Palliative Care Organization. http://www.nhpco.org/
files/public/Statistics_Research/2011_Facts_Figures.pdf. Accessed January
2012.
28. Saito AM, Landrum MB, Neville BA, et al. The effect on survival of
continuing chemotherapy to near death. BMC Palliative Care. 2011;10:14.
29. Connor SR, Pyenson B, Fitch K, et al. Comparing hospice and nonhospice
patient survival among patients who die within a three-year window.
J Pain Symptom Manage. 2007;33:238-246.
30. Massarelli E, Andre F, Liu DD, et al. A retrospective analysis of the
outcome of patients who have received two prior chemotherapy regimens
including platinum and docetaxel for recurrent non-small-cell lung cancer.
Lung Cancer. 2003;39:55-61.
31. Dy SM, Asch SM, Lorenz KA, et al. Quality of end-of-life care for
patients with advanced cancer in an academic medical center. J Palliat Med.
2011;14:451-457.
32. Smith TJ, Temin S, Alesi E, et al. American Society of Clinical Oncology
provisional clinical opinion: the integration of palliative care into standard
oncology care. J Clin Oncol. Epub 2012 Feb 6.
33. Temel JS, Greer JA, Admane S, et al. Longitudinal perceptions of
prognosis and goals of therapy in patients with metastatic non-small-cell lung
cancer: results of a randomized study of early palliative care. J Clin Oncol.
2011;29:2319-2326.
34. Hoverman JR, Cartwright TH, Patt DA, et al. Pathways, outcomes, and
costs in colon cancer: retrospective evaluations in two distinct databases.
J Oncol Pract. 2011;7:52s-59s.
35. Neubauer MA, Hoverman JR, Kolodziej M, et al. Cost effectiveness of
evidence-based treatment guidelines for the treatment of non-small-cell lung
cancer in the community setting. J Oncol Pract. 2010;6:12-18.
36. Azzoli CG, Baker S, Temin S, et al. American Society of Clinical
Oncology clinical practice guideline update on chemotherapy for stage IV non
small-cell lung cancer. J Clin Oncol. 2009;27:6251-6266.
37. McFarlane J, Riggins J, Smith TJ. SPIKE$: A six-step protocol for